Key facts
- It has raised $275.5M across 3 recorded rounds; the latest was Later Stage VC (Series C) ($160.5M) in Mar 2024.
- Obsidian Therapeutics has filed 1 Form D with the SEC, most recently Dec 2017 ($32.4M sold to 8 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 3 rounds
- ·Watchlist + deal alerts for Obsidian Therapeutics
Create free account
No card required
Funding rounds
3 roundsMar 2024Later Stage VC (Series C)$160.5M▮
Sep 2021Later Stage VC (Series B)$115.0M▮
About Obsidian Therapeutics
- Industry
- Drug Discovery
PA Mark — not yet priced
Obsidian Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Obsidian Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on Obsidian Therapeutics in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.